home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2848.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 2848
DOCN M94A2848
TI Safety of zalcitabine (ddC) in zidovudine (ZDV) intolerant individuals:
results of the European Expanded Access Study.
DT 9412
AU Moyle G; Goll A; Snape S; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):210 (abstract no. PB0268). Unique
Identifier : AIDSLINE ICA10/94369727
AB OBJECTIVE: To assess the tolerability of ddC in HIV positive individuals
intolerant to or had clinically failed on ZDV. METHODOLOGY: Patients
intolerant to or had failed on ZDV were provided with ddC (0.75 mg tid,
weight adjusted) via an open label access program. Recruitment ran from
March 1992 to end July 1993. Demographic data were collected at baseline
and patients were followed at 4 weekly intervals for drug related
events, clinical events and changes in surrogate markers (CD4 cell
count, weight, Karnofsky score). The relationship between baseline
characteristics and and peripheral neuropathy was specifically examined.
RESULTS: At closure of the program 517 patients had been enrolled with
at least one follow-up available on 423 patients 70% of the patients
were considered ZDV failures. 59% of patients had AIDS at baseline. The
mean baseline CD4 count was 52 cells/mm3 with 70% of the patients having
CD4 counts below 50 cells/mm3. Only 13% of patients terminated due to
drug related adverse events. Table 1 shows the incidence of adverse
events occurring during the study assessed as both related and unrelated
to ddC. Peripheral neuropathy was the most common drug related event.
Analysis of baseline characteristics suggest this toxicity occurred more
frequently in patients with a baseline AIDS diagnosis (p = 0.002) (Table
2). Data regarding changes in surrogate and clinical markers will also
be presented. TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: ddC
appears well tolerated in this patient population with unfavorable
baseline characteristics. Peripheral neuropathy is the most common drug
related toxicity occurring in 14.1% of the patients, and is more common
in patients commencing ddC with a baseline AIDS diagnosis.
Gastrointestinal disturbance including pancreatitis appears rare with
ddC. Hematologic disturbance also appears infrequent.
DE Bone Marrow Diseases/CHEMICALLY INDUCED Gastrointestinal
Diseases/CHEMICALLY INDUCED Human HIV Infections/*DRUG THERAPY
Pancreatitis/CHEMICALLY INDUCED Patient Acceptance of Health Care
Peripheral Nervous System Diseases/CHEMICALLY INDUCED Safety Treatment
Failure Zalcitabine/ADVERSE EFFECTS/*THERAPEUTIC USE
Zidovudine/*ADVERSE EFFECTS CLINICAL TRIAL MEETING ABSTRACT
MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).